H.R. 4278 · 117th Congress · House

To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.

Active· Referred to the Subcommittee on Health.
Introduced
Jun 30, 21
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

This bill requires the Government Accountability Office to study and report on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers.

Action Timeline

4
  1. JUL 01, 2021•Committee

    Referred to the Subcommittee on Health.

  2. JUN 30, 2021•IntroReferral

    Introduced in House

  3. JUN 30, 2021•IntroReferral

    Introduced in House

  4. JUN 30, 2021•IntroReferral

    Referred to the House Committee on Energy and Commerce.

Committees

2

Health Subcommittee

hsif14

Referred: Jul 1, 2021

Active

Energy and Commerce Committee

hsif00

Referred: Jun 30, 2021

Active